vs
AVADEL PHARMACEUTICALS PLC（AVDL）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
AVADEL PHARMACEUTICALS PLC的季度营收约是RIGEL PHARMACEUTICALS INC的1.1倍（$77.5M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 0.0%，领先384.0%），AVADEL PHARMACEUTICALS PLC同比增速更快（54.9% vs 21.2%），过去两年AVADEL PHARMACEUTICALS PLC的营收复合增速更高（99.6% vs 53.7%）
Avadel Pharmaceuticals是爱尔兰的专科制药企业，专注于睡眠障碍治疗药物的研发，产品覆盖医院及基层医疗场景，总部位于爱尔兰都柏林，在美国密苏里州圣路易斯、法国里昂均设有业务运营点。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
AVDL vs RIGL — 直观对比
营收规模更大
AVDL
是对方的1.1倍
$69.8M
营收增速更快
AVDL
高出33.7%
21.2%
净利率更高
RIGL
高出384.0%
0.0%
两年增速更快
AVDL
近两年复合增速
53.7%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $77.5M | $69.8M |
| 净利润 | $20.0K | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | 2.5% | 33.2% |
| 净利率 | 0.0% | 384.0% |
| 营收同比 | 54.9% | 21.2% |
| 净利润同比 | 100.8% | 1769.2% |
| 每股收益（稀释后） | $0.00 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVDLRIGL
| Q4 25 | — | $69.8M | ||
| Q3 25 | $77.5M | $69.5M | ||
| Q2 25 | $68.1M | $101.7M | ||
| Q1 25 | $52.5M | $53.3M | ||
| Q4 24 | $50.4M | $57.6M | ||
| Q3 24 | $50.0M | $55.3M | ||
| Q2 24 | $41.5M | $36.8M | ||
| Q1 24 | $27.2M | $29.5M |
净利润AVDLRIGL
| Q4 25 | — | $268.1M | ||
| Q3 25 | $20.0K | $27.9M | ||
| Q2 25 | $9.7M | $59.6M | ||
| Q1 25 | $-4.9M | $11.4M | ||
| Q4 24 | $-5.0M | $14.3M | ||
| Q3 24 | $-2.6M | $12.4M | ||
| Q2 24 | $-13.8M | $-1.0M | ||
| Q1 24 | $-27.3M | $-8.2M |
毛利率AVDLRIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | 90.7% | 95.6% | ||
| Q1 25 | 89.4% | 91.7% | ||
| Q4 24 | 90.5% | 89.9% | ||
| Q3 24 | 87.7% | 85.5% | ||
| Q2 24 | 93.3% | 92.4% | ||
| Q1 24 | 94.4% | 93.1% |
营业利润率AVDLRIGL
| Q4 25 | — | 33.2% | ||
| Q3 25 | 2.5% | 40.9% | ||
| Q2 25 | 13.0% | 60.1% | ||
| Q1 25 | -5.7% | 23.9% | ||
| Q4 24 | -6.5% | 28.9% | ||
| Q3 24 | -0.7% | 25.4% | ||
| Q2 24 | -30.7% | 1.2% | ||
| Q1 24 | -95.8% | -23.6% |
净利率AVDLRIGL
| Q4 25 | — | 384.0% | ||
| Q3 25 | 0.0% | 40.2% | ||
| Q2 25 | 14.2% | 58.6% | ||
| Q1 25 | -9.4% | 21.5% | ||
| Q4 24 | -10.0% | 24.9% | ||
| Q3 24 | -5.2% | 22.5% | ||
| Q2 24 | -33.3% | -2.8% | ||
| Q1 24 | -100.6% | -27.9% |
每股收益（稀释后）AVDLRIGL
| Q4 25 | — | $14.11 | ||
| Q3 25 | $0.00 | $1.46 | ||
| Q2 25 | $0.10 | $3.28 | ||
| Q1 25 | $-0.05 | $0.63 | ||
| Q4 24 | $-0.04 | $0.82 | ||
| Q3 24 | $-0.03 | $0.70 | ||
| Q2 24 | $-0.14 | $-0.06 | ||
| Q1 24 | $-0.30 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $91.6M | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $98.2M | $391.5M |
| 总资产 | $199.4M | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资AVDLRIGL
| Q4 25 | — | $155.0M | ||
| Q3 25 | $91.6M | $137.1M | ||
| Q2 25 | $81.5M | $108.4M | ||
| Q1 25 | $66.5M | $77.1M | ||
| Q4 24 | $73.8M | $77.3M | ||
| Q3 24 | $65.8M | $61.1M | ||
| Q2 24 | $71.4M | $49.1M | ||
| Q1 24 | $88.8M | $49.5M |
总债务AVDLRIGL
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M | ||
| Q1 24 | — | $60.0M |
股东权益AVDLRIGL
| Q4 25 | — | $391.5M | ||
| Q3 25 | $98.2M | $117.6M | ||
| Q2 25 | $90.7M | $81.9M | ||
| Q1 25 | $74.1M | $18.6M | ||
| Q4 24 | $73.8M | $3.3M | ||
| Q3 24 | $74.7M | $-14.6M | ||
| Q2 24 | $70.3M | $-29.9M | ||
| Q1 24 | $78.4M | $-31.7M |
总资产AVDLRIGL
| Q4 25 | — | $513.6M | ||
| Q3 25 | $199.4M | $242.5M | ||
| Q2 25 | $187.2M | $206.7M | ||
| Q1 25 | $167.9M | $176.0M | ||
| Q4 24 | $164.2M | $164.0M | ||
| Q3 24 | $158.3M | $139.4M | ||
| Q2 24 | $157.5M | $128.4M | ||
| Q1 24 | $167.9M | $126.5M |
负债/权益比AVDLRIGL
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $22.2M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $22.2M | — |
| 自由现金流率自由现金流/营收 | 28.7% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | 1110.25× | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AVDLRIGL
| Q4 25 | — | $22.0M | ||
| Q3 25 | $22.2M | $24.0M | ||
| Q2 25 | $12.7M | $30.5M | ||
| Q1 25 | $-8.2M | $-893.0K | ||
| Q4 24 | $7.9M | $14.5M | ||
| Q3 24 | $-6.9M | $21.7M | ||
| Q2 24 | $-18.2M | $302.0K | ||
| Q1 24 | $-29.7M | $-5.0M |
自由现金流AVDLRIGL
| Q4 25 | — | — | ||
| Q3 25 | $22.2M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率AVDLRIGL
| Q4 25 | — | — | ||
| Q3 25 | 28.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度AVDLRIGL
| Q4 25 | — | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金转化率AVDLRIGL
| Q4 25 | — | 0.08× | ||
| Q3 25 | 1110.25× | 0.86× | ||
| Q2 25 | 1.31× | 0.51× | ||
| Q1 25 | — | -0.08× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | — | 1.75× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
